GLP-1 Weight Loss Peptide Market: Efficacy, Brand Competition & Supply Chain Trends
Published: 12 7 月, 2026 23:43
Author: Andreas Wang
Abstract: The GLP-1 weight loss peptide market is dominated by semaglutide (Novo Nordisk) and tirzepatide (Eli Lilly), demonstrating 15-20% average weight reduction in clinical trials. Brand competition centers on efficacy, dosing convenience, and supply chain resilience amid global shortages. Key trends include oral formulations and compounding pharmacy alternatives. Product selection requires verifying GMP-certified manufacturing, third-party purity testing (>99%), and cold-chain logistics compliance (2-8°C). Market growth exceeds 30% CAGR, driven by obesity prevalence and expanded indications.